Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för sapitinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

8 träffar

Bibliografisk träff 2015-06-22

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.

Crafter C, Vincent JP, Tang E, Dudley P, James NH, Klinowska T, Davies BR.

Int J Oncol · research support, non-u.s. gov't; research-article; journal article · DOI 10.3892/ijo.2015.3062

Bibliografisk träff 2014-08-08

The first radiosynthesis of [(11)C]AZD8931 as a new potential PET agent for imaging of EGFR, HER2 and HER3 signaling.

Wang M, Gao M, Zheng QH.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2014.07.092

Bibliografisk träff 2014-07-09

Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man.

Ballard P, Swaisland HC, Malone MD, Sarda S, Ghiorghiu S, Wilbraham D.

Xenobiotica · journal article · DOI 10.3109/00498254.2014.938257

Bibliografisk träff 2014-05-31

Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer.

Kurata T, Tsurutani J, Fujisaka Y, Okamoto W, Hayashi H, Kawakami H, Shin E, Hayashi N, Nakagawa K.

Invest New Drugs · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s10637-014-0112-7

Bibliografisk träff 2014-05-30

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.

Mu Z, Klinowska T, Dong X, Foster E, Womack C, Fernandez SV, Cristofanilli M.

J Exp Clin Cancer Res · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1756-9966-33-47

Bibliografisk träff 2014-02-20

Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.

Morrison G, Fu X, Shea M, Nanda S, Giuliano M, Wang T, Klinowska T, Osborne CK, Rimawi MF, Schiff R.

Breast Cancer Res Treat · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1007/s10549-014-2878-x

Bibliografisk träff 2013-05-31

Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.

Barlaam B, Anderton J, Ballard P, Bradbury RH, Hennequin LF, Hickinson DM, Kettle JG, Kirk G, Klinowska T, Lambert-van der Brempt C, Trigwell C, Vincent J, Ogilvie D.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/ml400146c

Bibliografisk träff 2010-02-09

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.

Hickinson DM, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J, Beck S, Marshall G, Davenport S, Callis R, Mills E, Grosios K, Smith P, Barlaam B, Wilkinson RW, Ogilvie D.

Clin Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-09-2353